Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics Ltd. ( (AU:ATH) ) just unveiled an announcement.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Alterity Therapeutics Ltd as of February 4, 2025. This change in holding could influence Alterity’s market perception and stakeholder confidence, as JPMorgan’s investment decisions may impact the company’s financial and strategic positioning.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd is a biotechnology company focused on developing therapies for neurodegenerative diseases. Their primary focus is on creating innovative treatments to address conditions such as Alzheimer’s and Parkinson’s diseases, positioning themselves in the healthcare and pharmaceutical industry.
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $41.28M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.